Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q96PY6

UPID:
NEK1_HUMAN

ALTERNATIVE NAMES:
Never in mitosis A-related kinase 1; Renal carcinoma antigen NY-REN-55

ALTERNATIVE UPACC:
Q96PY6; G5E9Z3; Q05DG5; Q14CB7; Q5H9T1; Q6PIB8; Q96SS2; Q9H6P7; Q9Y594

BACKGROUND:
The Serine/threonine-protein kinase Nek1, recognized alternatively as Never in mitosis A-related kinase 1 and Renal carcinoma antigen NY-REN-55, is integral to cellular integrity and function. It exhibits kinase activity across serines, threonines, and tyrosines, facilitating DNA damage response and repair. Additionally, Nek1 plays a role in mitochondrial protection against cell death and is a key player in cilium assembly, indicating its broad impact on cell biology.

THERAPEUTIC SIGNIFICANCE:
Given Nek1's involvement in Short-rib thoracic dysplasia 6 with or without polydactyly and Amyotrophic lateral sclerosis 24, its study offers promising avenues for therapeutic intervention. The protein's critical functions in DNA damage repair and cell survival mechanisms present unique opportunities for developing targeted treatments for these and potentially other related disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.